Engaging Science & Business
contact us @ (650) 356-9207

See Who Selected our Software for Pharmaceutical Companies

  • Acceleron
    Acelleron aims to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies.
    acceleron
  • Adamas Pharmaceuticals, Inc.
    Adamas Pharmaceuticals is developing superior neuroprotective medicines for the treatment of central nervous system disorders.
    adamas
  • Alnylam Pharmaceuticals, Inc.
    Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on a breakthrough discovery that enables the creation of a broad new class of human therapeutics.
    alnylam
  • Ambrx, Inc.
    Ambrx is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.
    ambrx
  • Athersys, Inc.
    Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas.
    athersys
  • Balance Therapeutics
    Balance Therapeutics, Inc. is focused on developing therapeutics to address neurological disabilities resulting from excessive inhibition of the brain. Balance's pharmacological approach, based on technology licensed from Stanford University has demonstrated promising potential to address cognitive deficits in animal models of Down syndrome and Alzheimer's disease.
    balance therapeutics
  • Catalyst Biosciences
    Catalyst Biosciences is a leading biotechnology company focused on developing proteases as a therapeutic platform for inflammation, cardiovascular, and angiogenesis-based disorders.
    catalyst
  • Cerecor
    Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders.
    cerecor
  • Cytokinetics Inc.
    Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
    cytokinetics
  • Enanta Pharmaceuticals
    Enanta is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus, or HCV.
    enanta
  • Epizyme
    Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors.
    epizyme
  • FivePríme Therapeutics, Inc.
    FivePrime Therapeutics is developing treatments for cancer and diabetes and multiple leads in metabolic and immunologic diseases, oncology and regenerative medicine.
    fiveprime
  • FORMA Therapeutics
    At FORMA Therapeutics, we are passionate about discovering and developing medicines that will make a difference in cancer and other genetically-driven diseases. Our drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions.
    forma
  • IGM Biosciences
    IGM is a global leader in the protein engineering of IgM antibodies. Their mission is to improve the treatment of cancer and infectious diseases by creating novel IgM and IgA antibodies.
    igm
  • Intellia
    Intellia is a leading gene editing company focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system.
    intellia
  • Ipsen
    Ipsen US, comprised of Ipsen Biopharmaceuticals, Inc., and Ipsen Bioscience, Inc., is driven by a passion to improve the lives of patients. A search for innovative solutions to disabling conditions is at the heart of everything we do. We are inspired to find effective therapeutic options to treat diseases, relieve suffering, and bring value to the community.
    ipsen
  • Jaguar Animal Health
    Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion animals, horses and production animals.
    jaguar
  • Just
    Just is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. We believe that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.
    just
  • Karyopharm Therapeutics, Inc.
    is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
    kalobios
  • MacroGenics, Inc.
    MacroGenics is focused on applying its world-class antibody capabilities to discover, develop and deliver to patients novel biologics for the treatment of autoimmune disorders, cancer and infectious diseases.
    macrogenics
  • Medivation, Inc.
    Medivation is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs—Alzheimer’s disease, Huntington’s disease and castration-resistant prostate cancer.
    medivation
  • Mersana Therapeutics
    Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes.
    mersana
  • Momenta Pharmaceuticals, Inc.
    Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes.
    momenta
  • Nurix, Inc.
    Nurix is a leader in discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell. The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding of the ubiquitin proteasome system (UPS).
    nurix
  • OncoGenex
    OncoGenex is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
    oncogenex
  • PNIDigitalMedia
    PNI provides a proprietary transactional software platform that is used by leading retailers such as Costco, Walmart Canada, and CVS/pharmacy to sell millions of personalized products every year.
    pni
  • Prognosys Biosciences
    Prognosys is an early-stage biotechnology company focusing on the promising and rapidly developing field of personalized medicine. Prognosys carries out R&D in the area of novel assays and biomarker discovery, and uses next-generation sequencing technologies for the analysis of complex systems.
    prognosys
  • Retrophin
    is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options.
    retrophin
  • Sarepta Therapeutics
    Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases.
    sarepta
  • Spero Therapeutics
    Spero Therapeutics' vision extends beyond the current horizon of anti-infectives to find, develop, and advance groundbreaking therapeutics that meet critical patient needs in infectious disease.
    spero
  • Sutro
    Sutro is developing a new generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies.
    sutro
  • TerraVia
    TerraVia has pioneered an industrial biotechnology platform that harnesses the prolific oil-producing ability of microalgae. TerraVia uses standard industrial fermentation equipment to efficiently scale and accelerate the microalgae's natural oil production time to just a few days.
    terravia
  • Tetraphase Pharmaceuticals
    Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant (MDR) infections. Since the company's inception in 2006, Tetraphase has developed an antibiotics platform that offers the potential to dramatically improve the treatment of both broad spectrum and MDR bacterial infections.
    tetraphase
  • Viking Therapeutics
    Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking's R&D activities leverage the company's expertise in metabolism to develop innovative therapeutics that improve patients' lives.
    viking
  • Warp Drive Bio
    Warp Drive Bio is building a legendary company by deploying our innovative Genomic Mining and SMART™ platforms to discover new medicines that have the potential to make a significant difference in the lives of patients.
  • XOMA Corporation
    XOMA has built a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research.
    xoma

DOWNLOAD BROCHURE